These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 37367229)
1. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening. Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229 [TBL] [Abstract][Full Text] [Related]
2. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity. Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646 [TBL] [Abstract][Full Text] [Related]
3. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126 [TBL] [Abstract][Full Text] [Related]
5. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459 [TBL] [Abstract][Full Text] [Related]
6. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein. Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234 [TBL] [Abstract][Full Text] [Related]
7. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cao Y; Jian F; Zhang Z; Yisimayi A; Hao X; Bao L; Yuan F; Yu Y; Du S; Wang J; Xiao T; Song W; Zhang Y; Liu P; An R; Wang P; Wang Y; Yang S; Niu X; Zhang Y; Gu Q; Shao F; Hu Y; Yin W; Zheng A; Wang Y; Qin C; Jin R; Xiao J; Xie XS Cell Rep; 2022 Dec; 41(12):111845. PubMed ID: 36493787 [TBL] [Abstract][Full Text] [Related]
8. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979 [TBL] [Abstract][Full Text] [Related]
9. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH MAbs; 2022; 14(1):2021601. PubMed ID: 35030983 [TBL] [Abstract][Full Text] [Related]
10. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Wang P; Casner RG; Nair MS; Yu J; Guo Y; Wang M; Chan JF; Cerutti G; Iketani S; Liu L; Sheng Z; Chen Z; Yuen KY; Kwong PD; Huang Y; Shapiro L; Ho DD Emerg Microbes Infect; 2022 Dec; 11(1):147-157. PubMed ID: 34836485 [TBL] [Abstract][Full Text] [Related]
11. Superimmunity by pan-sarbecovirus nanobodies. Xiang Y; Huang W; Liu H; Sang Z; Nambulli S; Tubiana J; Williams KL; Duprex WP; Schneidman-Duhovny D; Wilson IA; Taylor DJ; Shi Y Cell Rep; 2022 Jun; 39(13):111004. PubMed ID: 35738279 [TBL] [Abstract][Full Text] [Related]
12. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747 [TBL] [Abstract][Full Text] [Related]
13. Broad sarbecovirus neutralization by a human monoclonal antibody. Tortorici MA; Czudnochowski N; Starr TN; Marzi R; Walls AC; Zatta F; Bowen JE; Jaconi S; Di Iulio J; Wang Z; De Marco A; Zepeda SK; Pinto D; Liu Z; Beltramello M; Bartha I; Housley MP; Lempp FA; Rosen LE; Dellota E; Kaiser H; Montiel-Ruiz M; Zhou J; Addetia A; Guarino B; Culap K; Sprugasci N; Saliba C; Vetti E; Giacchetto-Sasselli I; Fregni CS; Abdelnabi R; Foo SC; Havenar-Daughton C; Schmid MA; Benigni F; Cameroni E; Neyts J; Telenti A; Virgin HW; Whelan SPJ; Snell G; Bloom JD; Corti D; Veesler D; Pizzuto MS Nature; 2021 Sep; 597(7874):103-108. PubMed ID: 34280951 [TBL] [Abstract][Full Text] [Related]
14. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456 [TBL] [Abstract][Full Text] [Related]
15. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes. Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711 [TBL] [Abstract][Full Text] [Related]
16. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425 [TBL] [Abstract][Full Text] [Related]
17. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain. Wang Y; Zhang Z; Yang M; Xiong X; Yan Q; Cao L; Wei P; Zhang Y; Zhang L; Lv K; Chen J; Liu X; Zhao X; Xiao J; Zhang S; Zhu A; Gan M; Zhang J; Cai R; Zhuo J; Zhang Y; Rao H; Qu B; Zhang Y; Chen L; Dai J; Cheng L; Hu Q; Chen Y; Lv H; So RTY; Peiris M; Zhao J; Liu X; Mok CKP; Wang X; Zhao J Cell Rep; 2024 Jan; 43(1):113653. PubMed ID: 38175758 [TBL] [Abstract][Full Text] [Related]
18. Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor. Chia WN; Tan CW; Tan AWK; Young B; Starr TN; Lopez E; Fibriansah G; Barr J; Cheng S; Yeoh AY; Yap WC; Lim BL; Ng TS; Sia WR; Zhu F; Chen S; Zhang J; Kwek MSS; Greaney AJ; Chen M; Au GG; Paradkar PN; Peiris M; Chung AW; Bloom JD; Lye D; Lok S; Wang LF Sci Adv; 2023 Jul; 9(30):eade3470. PubMed ID: 37494438 [TBL] [Abstract][Full Text] [Related]
19. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. Tan CW; Chia WN; Young BE; Zhu F; Lim BL; Sia WR; Thein TL; Chen MI; Leo YS; Lye DC; Wang LF N Engl J Med; 2021 Oct; 385(15):1401-1406. PubMed ID: 34407341 [TBL] [Abstract][Full Text] [Related]
20. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]